 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 11, 2017 |
| Title |
The B-cell receptor confers super competitor status to lymphoma cells via GSK3β inhibition I |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by array
|
| Summary |
Similar to resting mature B cells, where the B-cell antigen receptor (BCR) is essential for cellular survival, surface BCR expression is conserved in most mature B cell lymphomas. The identification of activating BCR mutations and the growth disadvantage upon BCR knockdown of cells of certain lymphoma entities has led to the view that BCR signaling is required for tumour cell survival. Consequently, the BCR signaling machinery has become a new target in the therapy of B cell malignancies. Here, we studied the effects of BCR ablation on MYC-driven mouse B cell lymphomas and compared them to observations in human Burkitt lymphoma. Whereas BCR ablation did not, per se, significantly affect lymphoma growth, BCR-negative (BCR-) tumour cells rapidly disappeared in the presence of their BCR-expressing (BCR+) counterparts in vitro and in vivo. This required neither cellular contact, nor factors released by BCR+ tumour cells. Instead, BCR loss induced the rewiring of central carbon metabolism increasing the sensitivity of receptor-less lymphoma cells to nutrient restriction. The BCR attenuated GSK3β activity to support MYC-controlled gene expression. BCR- tumour cells exhibited increased GSK3β activity and were rescued from their competitive growth disadvantage by GSK3β. BCR-negative lymphoma variants that restored competitive fitness, normalized GSK3β following constitutive activation of the MAPK pathway, commonly through Ras mutations. Similarly, in Burkitt lymphoma, activating RAS mutations may propagate Ig-crippled tumour cells, which usually represent a minority of the tumour bulk. Thus, while BCR expression enhances lymphoma cell fitness, BCR-targeted therapies may profit from combinations with drugs targeting BCR-less tumour cells.
In this dataset, we included the expression data obtained from BCR-positive (BCR+) and BCR-negative (BCR-) lymphoma cells co-cultured for 4 days in presence or absence of GSK3b inhibitor, CHIR99021. These data were used to obtain genes that are regulated by the BCR through GSK3b inhibition.
|
| |
|
| Overall design |
BCR-positive (BCR.POS) and BCR-negative (BCR.NEG) lymphoma cells from 3 independent lymphomas (#2564, #2646, #2676) were co-cultured for 4 days in presence or absence of CHIR99021 (CT). BCR-positive and BCR-negative cells were sorted when counterselection of latter population was observed (4 days). Total RNA was extracted and gene expression profiling was performed on Affymetrix Mouse Gene 1.1 ST Arrays
|
| |
|
| Contributor(s) |
Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, Perucho L, Petrocelli V, Haake A, Lee AK, Bugatti M, Paul U, Van Anken E, Pasqualucci L, Rabadan R, Siebert R, Kempa S, Ponzoni M, Facchetti F, Rajewsky K, Casola S |
| Citation(s) |
28562582 |
| |
| Submission date |
Mar 28, 2017 |
| Last update date |
Jun 26, 2017 |
| Contact name |
Federica Zanardi |
| E-mail(s) |
[email protected], [email protected]
|
| Organization name |
IFOM, the FIRC Institute of Molecular Oncology
|
| Street address |
via Adamello 16
|
| City |
Milan |
| ZIP/Postal code |
20139 |
| Country |
Italy |
| |
|
| Platforms (1) |
| GPL11533 |
[MoGene-1_1-st] Affymetrix Mouse Gene 1.1 ST Array [transcript (gene) version] |
|
| Samples (12)
|
| GSM2552080 |
Lymphoma BCR-positive (ID # 2564) - Untreated |
| GSM2552081 |
Lymphoma BCR-negative (ID # 2564) - Untreated |
| GSM2552082 |
Lymphoma BCR-positive (ID # 2564) - CHIR99021 treated |
| GSM2552083 |
Lymphoma BCR-negative (ID # 2564) - CHIR99021 treated |
| GSM2552084 |
Lymphoma BCR-positive (ID # 2646) - Untreated |
| GSM2552085 |
Lymphoma BCR-negative (ID # 2646) - Untreated |
| GSM2552086 |
Lymphoma BCR-positive (ID # 2646) - CHIR99021 treated |
| GSM2552087 |
Lymphoma BCR-negative (ID # 2646) - CHIR99021 treated |
| GSM2552088 |
Lymphoma BCR-positive (ID # 2676) - Untreated |
| GSM2552089 |
Lymphoma BCR-negative (ID # 2676) - Untreated |
| GSM2552090 |
Lymphoma BCR-positive (ID # 2676) - CHIR99021 treated |
| GSM2552091 |
Lymphoma BCR-negative (ID # 2676) - CHIR99021 treated |
|
| This SubSeries is part of SuperSeries: |
| GSE97134 |
The B-cell receptor confers super competitor status to lymphoma cells via GSK3β inhibition |
|
| Relations |
| BioProject |
PRJNA380788 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE97132_RAW.tar |
53.7 Mb |
(http)(custom) |
TAR (of CEL) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...